The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients

De Couck,Marijke; van Brummelen,David; Schallier,Denis; De Grève,Jacques; Gidron,Yori

doi:10.3892/or.2013.2725

The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients

Authors:
- Marijke De Couck
- David van Brummelen
- Denis Schallier
- Jacques De Grève
- Yori Gidron
View Affiliations

Affiliations: Faculty of Medicine and Pharmacy, Free University of Brussels (VUB), Brussels, Belgium, Department of Medical Oncology, Oncological Center UZ Brussels, Brussels, Belgium
Published online on: September 9, 2013 https://doi.org/10.3892/or.2013.2725
Pages: 2435-2441

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies suggest that vagal nerve activity, indexed by heart rate variability (HRV), could have a prognostic role in cancer. However, most studies did not control adequately for confounders and included cardiac patients. Furthermore, the validity of this prognostic role needs to be tested in different types of cancer. The present study tested the prognostic role of HRV in prostate cancer (PC) and non-small cell lung cancer (NSCLC) patients, using a historical prospective design. HRV was derived from brief 10 sec ECGs obtained at approximately the time of diagnosis in 113 PC patients and 133 NSCLC patients. Outcomes included prostate-specific antigen (PSA) at 6 and 24 months in PC, and overall survival (OS) (for the full sample) and survival time (for the deceased patients) in NSCLC. Furthermore, the possible mediating role of C-reactive protein (CRP) was tested (in NSCLC), as well as whether age and stage moderated the relationship between HRV and prognosis in both types of cancer. In the PC patients, HRV significantly inversely predicted PSA levels at 6 and 24 months, independent of confounders. Furthermore, this was particularly significant in metastatic PC patients, indicating moderation by stage. In NSCLC patients, HRV did not predict OS and survival time, but it did positively predict survival time in patients under the age of 65, independent of confounders. Additionally, CRP was not found to mediate the relationship between HRV and OS or survival time in NSCLC. The present results partly support previous studies and extend them to two additional common types of cancer, using a more rigorous control over confounders. Together with recent experimental findings, these results propose a modulatory role of vagal nerve activity in cancer. Therefore, routine measurement of HRV in estimating prognosis in cancer may be considered.

View Figures

View References

1	Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Eastham JA: Prostate-specific antigen doubling time as a prognostic marker in prostate cancer. Nat Clin Pract Urol. 2:482–491. 2005. View Article : Google Scholar : PubMed/NCBI
3	de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM and Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. 2011.
4	Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D’Amico TA and Boyd JA: Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 115:5218–5227. 2009.PubMed/NCBI
5	Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL and Taron M: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 17:1160–1168. 2011. View Article : Google Scholar
6	Gandhi L and Janne PA: Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res. 18:3737–3742. 2012. View Article : Google Scholar : PubMed/NCBI
7	Brundage MD, Davies D and Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 122:1037–1057. 2002. View Article : Google Scholar : PubMed/NCBI
8	Marijon H, Bouyon A, Vignot S and Besse B: Prognostic and predictive factors in lung cancer. Bull Cancer. 96:391–404. 2009.PubMed/NCBI
9	Lee JH, Song EM, Sim YS, Ryu YJ and Chang JH: Forced expiratory volume in one second as a prognostic factor in advanced non-small cell lung cancer. J Thorac Oncol. 6:305–309. 2011.PubMed/NCBI
10	Valko M, Izakovic M, Mazur M, Rhodes CJ and Telser J: Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 266:37–56. 2004. View Article : Google Scholar : PubMed/NCBI
11	Faux SP, Tai T, Thorne D, Xu Y, Breheny D and Gaca M: The role of oxidative stress in the biological responses of lung epithelial cells to cigarette smoke. Biomarkers. 14:90–96. 2009. View Article : Google Scholar : PubMed/NCBI
12	Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H and Rusyn I: Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 14:1182–1190. 2007. View Article : Google Scholar : PubMed/NCBI
13	Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461–466. 2004. View Article : Google Scholar : PubMed/NCBI
14	Voronov E, Shouval DS, Krelin Y, et al: IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 100:2645–2650. 2003. View Article : Google Scholar : PubMed/NCBI
15	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar
16	Entschladen F, Drell TL IV, Lang K, Joseph J and Zaenker KS: Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 5:254–258. 2004. View Article : Google Scholar : PubMed/NCBI
17	Tracey KJ: Reflex control of immunity. Nat Rev Immunol. 9:418–428. 2009. View Article : Google Scholar : PubMed/NCBI
18	Ek M, Kurosawa M, Lundeberg T and Ericsson A: Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J Neurosci. 18:9471–9479. 1998.PubMed/NCBI
19	Pavithran P, Nandeesha H, Sathiyapriya V, Bobby Z and Madanmohan T: Short-term heart variability and oxidative stress in newly diagnosed essential hypertension. Clin Exp Hypertens. 30:486–496. 2009. View Article : Google Scholar : PubMed/NCBI
20	Vlcek M, Radikova Z, Penesova A, et al: Heart rate variability and catecholamines during hypoglycemia and orthostasis. Auton Neurosci. 143:53–57. 2008. View Article : Google Scholar : PubMed/NCBI
21	De Couck M, Mravec B and Gidron Y: You may need the vagus nerve to understand pathophysiology and to treat diseases. Clin Sci. 122:323–328. 2012.PubMed/NCBI
22	Gidron Y, Perry H and Glennie M: Does the vagus nerve inform the brain about preclinical tumours and modulate them? Lancet Oncol. 6:245–248. 2005. View Article : Google Scholar : PubMed/NCBI
23	Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 93:1043–1065. 1996. View Article : Google Scholar : PubMed/NCBI
24	Kuo TB, Lai CJ, Huang YT and Yang CC: Regression analysis between heart rate variability and baroreflex-related vagus nerve activity in rats. J Cardiovasc Electrophysiol. 16:864–869. 2005. View Article : Google Scholar : PubMed/NCBI
25	Hoffmann J, Grimm W, Menz V, Wied M, Sprenger A, Arnold R and Maisch B: Prognostic value of heart rate variability analysis in patients with carcinoid syndrome. Digestion. 63:35–42. 2001. View Article : Google Scholar : PubMed/NCBI
26	Fadul N, Strasser F, Palmer LJ, Yusuf SW, Guo Y, Li Z, Allo J and Bruera E: The association between autonomic dysfunction and survival in male patients with advanced cancer: a preliminary report. J Pain Symptom Manage. 39:283–290. 2010. View Article : Google Scholar : PubMed/NCBI
27	Chiang JK, Koo M, Kuo TB and Fu CH: Association between cardiovascular autonomic functions and time to death in patients with terminal hepatocellular carcinoma. J Pain Symptom Manage. 39:673–679. 2010. View Article : Google Scholar
28	Kim do H, Kim JA, Choi YS, Kim SH, Lee JY and Kim YE: Heart rate variability and length of survival in hospice cancer patients. J Korean Med Sci. 25:1140–1145. 2010.PubMed/NCBI
29	Mouton C, Ronson A, Razavi D, Delhaye F, Kupper N, Paesmans M, Moreau M, Nogaret JM, Hendlisz A and Gidron Y: The relationship between heart rate variability and time-course of carcinoembryonic antigen in colorectal cancer. Auton Neurosci. 166:96–99. 2012. View Article : Google Scholar : PubMed/NCBI
30	Crimmins EM, Johnston M, Hayward M and Seeman T: Age differences in allostatic load: an index of physiological dysregulation. Exp Gerontol. 38:731–734. 2003. View Article : Google Scholar : PubMed/NCBI
31	Pfleger CC, Flachs EM and Koch-Henriksen N: Social consequences of multiple sclerosis: clinical and demographic predictors - a historical prospective cohort study. Eur J Neurol. 17:1346–1351. 2010.PubMed/NCBI
32	Lerner-Geva L, Keinan-Boker L, Blumstein T, Boyko V, Olmar L, Mashiach S, Rabinovici J, Potashnik G, Lunenfeld E, Schenker JG, Shushan A, Fishman A, Cohen I, Vagman I and Lunenfeld B: Infertility, ovulation induction treatments and the incidence of breast cancer - a historical prospective cohort of Israeli women. Breast Cancer Res Treat. 100:201–212. 2006. View Article : Google Scholar : PubMed/NCBI
33	Thong T, Li K, McNames J, Aboy M and Goldstein B: Accuracy of ultra-short heart rate variability measures. Engineering in Medicine and Biology Society. Proc 25th Annual Int Conference of the IEEE. 3:2424–2427. 2003.
34	Nussinovitch U, Elishkevitz KP, Katz K, Nussinovitch M, Segev S, Volovitz B and Nussinovitch N: Reliability of ultra-short ECG indices for heart rate variability. Ann Noninvasive Electrocardiol. 16:117–122. 2011. View Article : Google Scholar : PubMed/NCBI
35	Hodgart E and Macfarlane PW: 10 second heart rate variability. Comp Cardiol. 31:217–220. 2004.
36	Schipke JD, Pelzer M and Arnold G: Effect of respiration rate on short-term heart rate variability. J Clin Basic Cardiol. 2:92–94. 1999.
37	Poyhonen M, Syvaoja S, Hartikainen J, Ruokonen E and Takala J: The effect of carbon dioxide, respiratory rate and tidal volume on human heart rate variability. Acta Anaesthesiol Scand. 48:93–101. 2004.PubMed/NCBI
38	Strauss-Blasche G, Moser M, Voica M, McLeod DR, Klammer N and Marktl W: Relative timing of inspiration and expiration affects respiratory sinus arrhythmia. Clin Exp Pharmacol Physiol. 27:601–606. 2000. View Article : Google Scholar : PubMed/NCBI
39	Brown JK, Cooley ME, Chernecky C and Sarna L: A symptom cluster and sentinel symptom experienced by women with lung cancer. Oncol Nurs Forum. 38:E425–E435. 2011. View Article : Google Scholar : PubMed/NCBI
40	Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS and Gulsvik A: Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med. 173:1316–1325. 2006. View Article : Google Scholar : PubMed/NCBI
41	Katona PG and Jih F: Respiratory sinus arrhythmia: noninvasive measure of parasympathetic cardiac control. J Appl Physiol. 39:801–805. 1975.PubMed/NCBI
42	Cassart M, Pettiaux N, Gavenois PA, Pavia M and Estenne M: Effect of chronic hyperinflation on diaphragm length and surface area. Am J Respir Crit Care Med. 156:504–508. 1997. View Article : Google Scholar : PubMed/NCBI
43	Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, Younes M, Antonacci F, Forgez P, Dechartres A, Massard G, Damotte D and Régnard JF: Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 142:1161–1167. 2011. View Article : Google Scholar : PubMed/NCBI
44	Hamilton RM, McKechnie PS and Macfarlane PW: Can cardiac vagal tone be estimated from the 10-second ECG? Int J Cardiol. 95:109–115. 2004. View Article : Google Scholar : PubMed/NCBI
45	Dekker JM, Schouten EG, Klootwijk P, Pool J, Swenne CA and Kromhout D: Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study. Am J Epidemiol. 145:899–908. 1997. View Article : Google Scholar : PubMed/NCBI
46	O’Donnell K, Brydon L, Wright CE and Steptoe A: Self-esteem levels and cardiovascular and inflammatory responses to acute stress. Brain Behav Immun. 22:1241–1247. 2008.PubMed/NCBI
47	Erin N, Akdas Barkan G, Harms JF and Clawson GA: Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters substance P level. Regul Pept. 151:35–42. 2008. View Article : Google Scholar : PubMed/NCBI
48	Erin N, Boyer PJ, Bonneau RH, Clawson GA and Welch DR: Capsaicin-mediated denervation of sensory neurons promotes mammary tumor metastasis to lung and heart. Anticancer Res. 24:1003–1009. 2004.PubMed/NCBI
49	Erin N, Duymuş O, Oztürk S and Demir N: Activation of vagus nerve by semapimod alters substance P levels and decreases breast cancer metastasis. Regul Pept. 179:101–108. 2012. View Article : Google Scholar : PubMed/NCBI